Frontiers in Immunology · 10 Nov 2026
Dendritic cell-targeting virus-like particles as mRNA carriers induce Th1-skewed humoral and cellular immunity
Fangfeng Yuan, DongSoo Yun, Sofiya Ismagilova, Jianzhu Chen
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Messenger RNA (mRNA) vaccines have emerged as a powerful vaccination platform, yet efficient and targeted delivery of mRNA to professional antigen-presenting cells (APCs) remains a major challenge. Here, we developed a dendritic cell (DC)-targeting virus-like particle (DVLP) platform for mRNA delivery by combining human immunodeficiency virus (HIV) Gag fused with the bacteriophage MS2 coat protein, which recognizes mRNA bearing MS2 stem-loop sequences and an engineered Sindbis virus glycoprotein mutant (SV-Gmt) that preferentially targets dendritic cells. African swine fever virus (ASFV) P30 was employed as a model antigen to evaluate platform performance. In vitro , SV-Gmt-pseudotyped VLPs encapsulating P30 mRNA (DVLP-P30) preferentially delivered antigen mRNA to dendritic cells compared with broad-tropic vesicular stomatitis virus G protein (VSV-G)-pseudotyped VLPs encapsulating P30 mRNA (VSV-G VLP-P30). In mice, vaccination with DVLP-P30 induced significantly higher P30-specific antibody responses than VSV-G VLP-P30. Enhanced humoral immunity was accompanied by increased frequencies of CD4 + and CD8 + effector memory T cells, indicating improved generation of antigen-specific immune memory. Notably, DC-targeted mRNA delivery promoted stronger interferon-γ responses and increased IgG2a production, consistent with a Type 1 helper T cell (Th1)-skewed immune profile. Together, these findings demonstrate that DC-targeting VLPs function as effective mRNA carriers and enhance both the magnitude and quality of vaccine-induced immunity. This work establishes a versatile platform for targeted mRNA delivery and supports further development of DVLPs for prophylactic and therapeutic vaccination.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (14)
What it cites, from open citation data, with Crossref's record of each.